From the Guidelines
I'm not familiar with "Cobenfy" as it doesn't appear to be a recognized medication, treatment, or medical procedure in the provided evidence 1. Without additional context about what Cobenfy refers to, I cannot provide specific instructions on how to use it. If you're referring to a specific medication, treatment protocol, or health product, please provide more details so I can give you accurate information. Some medications and treatments mentioned in the guidelines include:
- Nivolumab plus ipilimumab followed by nivolumab until disease progression
- Nivolumab plus relatlimab
- Nivolumab
- Pembrolizumab
- Vemurafenib plus cobimetinib
- Dabrafenib plus trametinib
- Encorafenib plus binimetinib If you've encountered this term in a medical context, I'd recommend consulting with a healthcare provider for clarification, as using unfamiliar treatments without proper guidance could pose health risks. If you meant a different medication or procedure, please clarify the name so I can provide appropriate instructions based on the latest evidence 1.
From the Research
Mechanism of Action of Cobenfy
- Cobenfy, also known as xanomeline-trospium, is a novel antipsychotic that operates through a unique mechanism, activating cholinergic receptors to mitigate psychotic symptoms while minimizing the common adverse effects associated with dopamine-blocking agents 2.
- Xanomeline has a novel mechanism of action for the treatment of schizophrenia, acting as a dual muscarinic-1 and muscarinic-4 preferring receptor agonist 3.
Efficacy of Cobenfy
- Clinical trials, particularly the EMERGENT-2 and EMERGENT-3 studies, demonstrated that Cobenfy substantially improved both positive and negative symptoms of schizophrenia, achieving greater reductions in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo 2.
- Two phase 3 trials with xanomeline-trospium saw significant reductions in PANSS positive and negative subscales, PANSS Marder negative factors, and CGI-S scale scores compared to placebo 3.
- The Cohen's d effect for the primary endpoint was around 0.60 in both trials, indicating a moderate to large effect size 3.
Safety and Tolerability of Cobenfy
- Cobenfy exhibited a favorable safety profile, with fewer incidences of weight gain and extrapyramidal symptoms compared to traditional antipsychotics 2.
- However, it is associated with side effects such as nausea, dyspepsia, and constipation 2.
- The medication was well-tolerated in all clinical trials, with the most common adverse events being rated as mild-to-moderate 3.